




LISTING OF CLAIMS **RECEIVED**

1-17: (canceled)

MAR 03 2004


18. (currently amended) A compound selected from those of formula (I) :



wherein

- ✓ R_1 , R_2 , R_3 and R_4 independently represent hydrogen, halogen or alkyl, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxy carbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl,
or, taken in pairs, form together with the carbon atoms to which they are bonded a phenyl ring,
- ✓ L_1 and L_2 each represents hydrogen or together form $-CH_2-CH_2-$,
- ✓ X_1 , attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X_2 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),
or,
 X_1 and X_2 , together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form $(C_4-C_7)cycloalkyl$ wherein one carbon of the cycloalkyl ring is substituted by G ,
- ✓ X_3 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),

✓ G represents



wherein :

T_3 represents optionally substituted heteroaryl or optionally substituted heteroarylalkyl,

wherein :

- the term "alkyl" denotes linear or branched group containing having from 1 to 6 carbon,
- the term "alkoxy" denotes linear or branched alkyl-oxy containing having from 1 to 6 carbon,
- the term "aryl" denotes phenyl, naphthyl or biphenyl,
- the term "heteroaryl" denotes a benzodioxinyl group,
- the expression "optionally substituted" associated with aryl, arylalkyl, heteroaryl and heteroarylalkyl denotes that those groups are unsubstituted or substituted on the cyclic moiety by one or more halogen and/or alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxy carbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, wherein heteroaryl and heteroarylalkyl may in addition be substituted by oxo, its

enantiomers and diastereoisomers thereof, and addition salts thereof with a pharmaceutically acceptable acid or base.

19. (previously presented) A compound of claim 18, wherein L₁ and L₂ each represents hydrogen.
20. (previously presented) A compound of claim 18, wherein L₁ and L₂ together form -CH₂-CH₂-.
21. (previously presented) A compound of claim 18, wherein R₁ and R₄ each represents hydrogen.
22. (previously presented) A compound of claim 18, wherein R₂ and R₃ are selected from halogen and alkyl.
23. (previously presented) A compound of claim 18, wherein X₁ is attached at the 2 position of the phenyl ring.
24. (previously presented) A compound of claim 18, wherein X₁ represents a bond and X₂ represents halogen or alkyl or alkoxy.
25. (previously presented) A compound of claim 18, wherein X₃ represents hydrogen.
26. (previously presented) A compound of claim 18, wherein R₃ and R₄ together with carbon to which they are bonded form a phenyl ring and L₁ and L₂ together form -CH₂-CH₂-.
27. (canceled)
28. (previously presented) A compound of claim 18, wherein X₁ and X₂, together with two carbon in the 2 and 3 position of the aromatic ring to which they are bonded, form (C₄-C₇)cycloalkyl.

29. (previously presented) A compound of claim 18 that is *N*-(3-chloro-4-methylphenyl)-*N'*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}urea, its addition salts thereof with a pharmaceutically acceptable acid or base
30. (canceled)
31. (canceled)
32. (previously presented) A compound of Claim 18 that is *N*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}-*N'*-(3,4-dimethylphenyl)urea, its addition salts thereof with a pharmaceutically acceptable acid or base
33. (currently amended) A method for treating an animal or human living body afflicted with depression, anxiety, schizophrenia, Parkinson's disease, Alzheimer's disease, attention deficit disorder, cognitive disorders, libido disorders and sexual dysfunction, slow wave sleep disorders, drug abuse, and impulsive behaviour disorders comprising the step of administering to the living body an amount of a compound of Claim 18 which is effective for alleviation of said condition.
34. (currently amended) A pharmaceutical composition useful for treating an animal or human living body afflicted with a condition selected from depression, anxiety, schizophrenia, Parkinson's disease, Alzheimer's disease, attention deficit disorder, cognitive disorders, libido disorders and sexual dysfunction, slow wave sleep disorders, drug abuse, and impulsive behaviour disorders comprising a compound of claim 18 in combination with one or more pharmaceutically acceptable, excipients or vehicles.